Influence of quercetin on the pharmacokinetics of ranolazine in rats and in vitro models

Drug Development and Industrial Pharmacy

Volumn 39, Issue 6, 2013, Pages 873-879

  Babu, P Ravindra ^a   Babu, K Naveen ^a   Peter, P L Haroled ^a   Rajesh, K ^b   Babu, P Jawahar ^c  

^a KVSR SIDDHARTHA COLLEGE OF PHARMACEUTICAL SCIENCES   (India)

^b UNIVERSITY OF MISSISSIPPI   (United States)

^c Green Royal Academy of Pharmaceutical Education and Sciences   (India)

Author keywords

Chicks; Chronic stable angina; P glycoprotein; Quercetin; Ranolazine

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN; QUERCETIN; RANOLAZINE; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CHICK; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; DRUG POTENTIATION; DRUG TRANSPORT; IN VITRO STUDY; INTESTINE ABSORPTION; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; SINGLE DRUG DOSE;

ACETANILIDES; ANIMALS; ANTIOXIDANTS; CHICKENS; DRUG INTERACTIONS; ENZYME INHIBITORS; INTESTINAL ABSORPTION; MALE; ORGAN CULTURE TECHNIQUES; P-GLYCOPROTEIN; PIPERAZINES; QUERCETIN; RATS; RATS, WISTAR; SODIUM CHANNEL BLOCKERS;

EID: 84877050531     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.707209     Document Type: Article

References (21)

1. The American Heart Association. (2008). Heart disease and stroke statistics: Biostatistical fact sheets. Circulation, 117:4-12.
2. Rosamond W, Flegal K, Furie K. (2008). For the American Heart Association Statistics Committee and the Stroke Statistics Committee. Heart disease and stroke statistics, e53-e55.
3. Jean-Louis G, Franck P, Alain CS. (2011). Update on the medical treatment of stable angina. Archives Cardiovasc Dis, 104:536-544.
4. Nash DT, Nash SD. (2008). Ranolazine for chronic stable angina. Lancet, 372:1335-1341.
5. Parker JD, Parker JO. (2012). Stable Angina Pectoris: The Medical Management of Symptomatic Myocardial Ischemia. Can J Cardiol, 28:S70-S80.
6. Sossalla S, Maier LS. (2012). Role of ranolazine in angina, heart failure, arrhythmias, and diabetes. Pharmacol Ther, 133:311-323.
7. Lairon D, Amiot MJ. (1999). Flavonoids in food and natural antioxidants in wine. Curr Opin Lipidol, 10:23-28.
8. Soleas GJ, Diamandis EP, Goldberg DM. (1997). Wine as a biological fluid: history, production, and role in disease prevention. J Clin Lab Anal, 11:287-313.
9. Formica JV, Regelson W. (1995). Review of the biology of Quercetin and related bioflavonoids. Food Chem Toxicol, 33:1061-1080.
10. Havsten B. (1983). Flavonoids, A class of natural products of high pharmacological potency. Biochem Pharmacol, 32:1141-1148.
11. Annapurna A, Reddy CS, Akondi RB, Rao SR. (2009). Cardioprotective actions of two bioflavonoids, quercetin and rutin, in experimental myocardial infarction in both normal and streptozotocin-induced type I diabetic rats. J Pharm Pharmacol, 61:1365-1374.
12. Caltagirone S, Rossi C, Poggi A, Ranelletti FO, Natali PG, Brunetti M et al. (2000). Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential. Int J Cancer, 87:595-600.
13. Sanhueza J, Valdes J, Campos R, Garrido A, Valenzuela A. (1992). Changes in the xanthine dehydrogenase/xanthine oxidase ratio in the rat kidney subjected to ischemia-reperfusion stress: preventive effect of some flavonoids. Res Commun Chem Pathol Pharmacol, 78:211-218.
14. Barthe L, Bessont M, Woodley JF, Houin G. (1998). The improved everted gut sac: a simple method to study intestinal P-glycoprotein. International Journal of Pharmaceutics, 173:255-258.
15. Tanaka K, Fujita T, Yamamoto Y, Murakami M, Yamamoto A, Muranishi S. (1996). Enhancement of intestinal transport of thyrotropin-releasing hormone via a carrier-mediated transport system by chemical modification with lauric acid. Biochim Biophys Acta, 1283:119-126.
16. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J et al.; MARISA Investigators. (2004). Anti-ischemic effects and longterm survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol, 43:1375-1382.
17. Jerling M. (2006). Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet, 45:469-491.
18. Krishna R, Mayer LD. (2000). Multidrug resistance (MDR) in cancer. Mechanisms, reversal using modulators of MDR and the role of MDR modulators in influencing the pharmacokinetics of anticancer drugs. Eur J Pharm Sci, 11:265-283.
19. Jerling M, Huan BL, Leung K, Chu N, Abdallah H, Hussein Z. (2005). Studies to investigate the pharmacokinetic interactions between ranolazine and ketoconazole, diltiazem, or simvastatin during combined administration in healthy subjects. J Clin Pharmacol, 45:422-433.
20. Meerum Terwogt JM, Malingre MM, Beijnen JH, ten Bokkel Huinink WW, Rosing H, Koopman FJ et al. (1999). Coadministration of oral cyclosporin A enables oral therapy with paclitaxel. Clin Cancer Res, 5:3379-3384.
21. Sha X, Fang X. (2004). Transport characteristics of 9- nitrocamptothecin in the human intestinal cell line Caco-2 and everted gut sacs. Int J Pharm, 272:161-171.